Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a ...

British industry leaders fear tariffs imposed by President Trump could disrupt the supply and even the price of drugs ...

Meghan Trainor and husband Daryl Sabara opened up about their health journeys, which has included them both opting to take ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

Novo Nordisk’s SOUL trial confirms that oral semaglutide significantly reduces the risk of heart attack, stroke, and ...

Weight loss platform Noom launched a full-page print ad in The Wall Street Journal this week, calling on policymakers to create new guidance around expensive drugs, as compounded GLP-1s are set to be ...

But this is just the start. GLP-1 drugs (specifically Novo Nordisk’s Ozempic, Rybelsus and Wegovy and Eli Lilly’s Mounjaro ...

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability issue of obesity medications such as Wegovy and Zepbound.

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type ...